BTG’s (BTG) “House Stock” Rating Reiterated at Shore Capital

Shore Capital restated their house stock rating on shares of BTG (LON:BTG) in a report released on Tuesday,Digital Look reports.

BTG Price Performance

BTG has a 12 month low of GBX 512.50 and a 12 month high of GBX 853. The stock has a market capitalization of £3.26 billion and a P/E ratio of 29.47.

About BTG

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease.